Neurofilaments and progranulin are related to atrophy in frontotemporal lobar degeneration - A transdiagnostic study cross-validating atrophy and fluid biomarkers.
amyloid
atrophy
fluid biomarkers
frontotemporal dementia
frontotemporal lobar degeneration
magnetic resonance imaging
neurofilaments
phospho‐tau
progranulin
tau
ubiquitin
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
12 Jun 2024
12 Jun 2024
Historique:
revised:
22
03
2024
received:
21
12
2023
accepted:
24
03
2024
medline:
12
6
2024
pubmed:
12
6
2024
entrez:
12
6
2024
Statut:
aheadofprint
Résumé
Frontotemporal lobar degeneration (FTLD) encompasses behavioral variant frontotemporal dementia (bvFTD), progressive supranuclear palsy, corticobasal syndrome/degeneration, and primary progressive aphasias (PPAs). We cross-validated fluid biomarkers and neuroimaging. Seven fluid biomarkers from cerebrospinal fluid and serum were related to atrophy in 428 participants including these FTLD subtypes, logopenic variant PPA (lvPPA), Alzheimer's disease (AD), and healthy subjects. Atrophy was assessed by structural magnetic resonance imaging and atlas-based volumetry. FTLD subtypes, lvPPA, and AD showed specific profiles for neurofilament light chain, phosphorylated heavy chain, tau, phospho-tau, amyloid beta Results specify biomarker and atrophy patterns in FTLD and AD supporting differential diagnosis. They identify neurofilaments and progranulin in interaction with structural imaging as promising candidates for monitoring disease progression and therapy. Study cross-validated neuroimaging and fluid biomarkers in dementia. Five kinds of frontotemporal lobar degeneration and two variants of Alzheimer's disease. Study identifies disease-specific fluid biomarker and atrophy profiles. Fluid biomarkers and atrophy interact in a disease-specific way. Neurofilaments and progranulin are proposed as biomarkers for diagnosis and therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615‐1621. doi:10.1212/wnl.58.11.1615
Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet (London, England). 2006;368(9533):387‐403.
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456‐2477.
Gorno‐Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006‐1014.
Association AP. Diagnostic and statistical manual of mental disorders (DSM‐5®). 5 ed. American Psychiatric Publishing; 2013.
Grossman M. Biomarkers in the primary progressive aphasias. Aphasiology. 2014;28(8‐9):922‐940.
Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol. 2017;13(7):406.
Skillbäck T, Farahmand B, Bartlett JW, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21):1945‐1953.
Zetterberg H, Skillbäck T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73(1):60‐67.
Alcolea D, Vilaplana E, Suárez‐Calvet M, et al. CSF sAPPß, YKL‐40, and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017;89(2):178‐188.
Zerr I, Schmitz M, Karch A, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer Dement. 2018;14(6):751‐763.
Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199. doi:10.3389/fnins.2021.679199
Wang SY, Chen W, Xu W, et al. Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta‐analysis. J Alzheimer's Dis. 2019;72(4):1353‐1361. doi:10.3233/JAD‐190615
Steinacker P, Semler E, Anderl‐Straub S, et al. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology. 2017;88(10):961‐969.
Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75(1):116‐126.
Steinacker P, Anderl‐Straub S, Diehl‐Schmid J, et al. Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018;91(15):e1390‐e1401.
Rohrer JD, Woollacott IOC, Dick KM, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329‐1336.
Buée L, Bussière T, Buée‐Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev. 2000;33(1):95‐130.
Rivero‐Santana A, Ferreira D, Perestelo‐Perez L, et al. Cerebrospinal fluid biomarkers for the differential diagnosis between Alzheimer's disease and frontotemporal lobar degeneration: systematic review, HSROC analysis, and confounding factors. J Alzheimer's Dis. 2017;55(2):625‐644.
Santangelo R, Coppi E, Ferrari L, et al. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia. J Alzheimer's Dis. 2015;43(4):1429‐1440.
Paraskevas GP, Kasselimis D, Kourtidou E, et al. Cerebrospinal fluid biomarkers as a diagnostic tool of the underlying pathology of primary progressive aphasia. J Alzheimer's Dis. 2017;55(4):1453‐1461.
Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609‐622.
Aerts MB, Esselink RAJ, Bloem BR, Verbeek MM. Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord. 2011;26(1):169‐173.
Itoh N, Arai H, Urakami K, et al. Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 2001;50(2):150‐156.
Dobson CM. Protein folding and misfolding. Nature. 2003;426(6968):884‐890.
Motter R, Vigo‐Pelfrey C, Kholodenko D, et al. Reduction of ß‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38(4):643‐648.
Selkoe DJ. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol. 2004;6(11):1054‐1061.
Bibl M, Mollenhauer B, Lewczuk P, et al. Cerebrospinal fluid tau, p‐tau 181 and amyloid‐ß38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord. 2011;31(1):37‐44.
Baker M, Mackenzie IR, Pickering‐Brown SM, et al. Mutations in progranulin cause tau‐negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916‐919.
Van Damme P, Van Hoecke A, Lambrechts D, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol. 2008;181(1):37‐41.
Otto M, Ludolph AC, Landwehrmeyer B, et al. Konsortium zur Erforschung der frontotemporalen Lobärdegeneration. Nervenarzt. 2011;82(8):1002.
Wagner M, Lorenz G, Volk AE, et al. Clinico‐genetic findings in 509 frontotemporal dementia patients. Mol Psychiatry. 2021;26(10):5824‐5832.
Association WM. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191‐2194.
Folstein MF, Folstein SE, McHugh PR. “Mini‐mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189‐198.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412‐2414.
Knopman DS, Kramer JH, Boeve BF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131(11):2957‐2968.
Knopman DS, Weintraub S, Pankratz VS. Language and behavior domains enhance the value of the clinical dementia rating scale. Alzheimer Dement. 2011;7(3):293‐299.
Feneberg E, Steinacker P, Volk AE, et al. Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. J Neural Transm. 2016;123(3):289‐296.
Oeckl P, Steinacker P, von Arnim CAF, et al. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration. J Proteome Res. 2014;13(11):4518‐4525.
Huppertz H‐J, Kröll‐Seger J, Klöppel S, Ganz RE, Kassubek J. Intra‐and interscanner variability of automated voxel‐based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage. 2010;49(3):2216‐2224.
Huppertz H‐J, Möller L, Südmeyer M, et al. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Mov Disord. 2016;31(10):1506‐1517.
Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839‐851.
Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. Neuroimage. 1995;2(2):89‐101.
Mazziotta J, Toga A, Evans A, et al. A probabilistic atlas and reference system for the human brain: international Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 2001;356(1412):1293‐1322.
Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95‐113.
Ashburner J, Barnes G, Chen C, et al. SPM12 manual. Wellcome Trust Centre for Neuroimaging. 2014.
Shattuck DW, Mirza M, Adisetiyo V, et al. Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage. 2008;39(3):1064‐1080.
Makris N, Goldstein JM, Kennedy D, et al. Decreased volume of left and total anterior insular lobule in schizophrenia. Schizophr Res. 2006;83(2‐3):155‐171.
Frazier JA, Chiu S, Breeze JL, et al. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry. 2005;162(7):1256‐1265.
Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31(3):968‐980.
Goldstein JM, Seidman LJ, Makris N, et al. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry. 2007;61(8):935‐945.
Meeter LH, Dopper EG, Jiskoot LC, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623‐636.
Permutation Tests for Regression. ANOVA and Comparison of Signals: The permuco Package. 2018. https://CRAN.R‐project.org/package=permuco
Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23:S208‐S219.
Diedrichsen J, Balsters JH, Flavell J, Cussans E, Ramnani N. A probabilistic MR atlas of the human cerebellum. Neuroimage. 2009;46(1):39‐46.
Sjögren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001;66(3):510‐516.
Jonsson M, Zetterberg H, Van Straaten E, et al. Cerebrospinal fluid biomarkers of white matter lesions—cross‐sectional results from the LADIS study. Eur J Neurol. 2010;17(3):377‐382.
Cairns NJ, Neumann M, Bigio EH, et al. TDP‐43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227‐240.
Abu‐Rumeileh S, Oeckl P, Baiardi S, et al. CSF ubiquitin levels are higher in Alzheimer's disease than in frontotemporal dementia and reflect the molecular subtype in prion disease. Biomolecules. 2020;10(4):497. doi:10.3390/biom10040497
Callen DJA, Black SE, Gao F, Caldwell CB, Szalai JP. Beyond the hippocampus: mRI volumetry confirms widespread limbic atrophy in AD. Neurology. 2001;57(9):1669‐1674.
Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN. Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology. 2001;57(10):1756‐1763.
Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta‐analysis involving 1351 patients. Neuroimage. 2009;47(4):1196‐1206.
Bisenius S, Neumann J, Schroeter ML. Validating new diagnostic imaging criteria for primary progressive aphasia via anatomical likelihood estimation meta‐analyses. Eur J Neurol. 2016;23(4):704‐712.
Gorno‐Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008;71(16):1227‐1234.
Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: erosion of the language network. Neuroimage. 2010;49(1):984‐993.
Schroeter ML, Raczka K, Neumann J, Von Cramon DY. Towards a nosology for frontotemporal lobar degenerations—a meta‐analysis involving 267 subjects. Neuroimage. 2007;36(3):497‐510.
Schroeter ML, Laird AR, Chwiesko C, et al. Conceptualizing neuropsychiatric diseases with multimodal data‐driven meta‐analyses — The case of behavioral variant frontotemporal dementia. Cortex. 2014;57:22‐37.
Whitwell JL, Przybelski SA, Weigand SD, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain. 2009;132(11):2932‐2946.
Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol. 2007;6(11):1004‐1014.
Davies RR, Graham KS, Xuereb JH, Williams GB, Hodges JR. The human perirhinal cortex and semantic memory. Eur J Neurosci. 2004;20(9):2441‐2446.
Davies RR, Scahill VL, Graham A, Williams GB, Graham KS, Hodges JR. Development of an MRI rating scale for multiple brain regions: comparison with volumetrics and with voxel‐based morphometry. Neuroradiology. 2009;51(8):491‐503.
Lombardi J, Mayer B, Semler E, et al. Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimers Dement. 2021;17(10):1595‐1609. doi:10.1002/alz.12323
Albrecht F, Bisenius S, Neumann J, Whitwell J, Schroeter ML. Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy — A double‐validation whole‐brain meta‐analysis. Neuroimage Clin. 2019;22:101722. doi:10.1016/j.nicl.2019.101722
Stezin A, Lenka A, Jhunjhunwala K, Saini J, Pal PK. Advanced structural neuroimaging in progressive supranuclear palsy: where do we stand? Parkinsonism Relat Disord. 2017;36:19‐32.
Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be? Mov Disord. 2017;32(7):955‐971.
Albrecht F, Bisenius S, Morales Schaack R, Neumann J, Schroeter ML. Disentangling the neural correlates of corticobasal syndrome and corticobasal degeneration with systematic and quantitative ALE meta‐analyses. NPJ Parkinsons Dis. 2017;3:12. doi:10.1038/s41531‐017‐0012‐6
Gibb WRG, Luthert PJ, Marsden CD. Corticobasal Degeneration. Brain. 1989;112(5):1171‐1192.
Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large‐scale human brain networks. Neuron. 2009;62(1):42‐52.
Guo Y, You J, Zhang Y, et al. Plasma proteomic profiles predict future dementia in healthy adults. Nat Aging. 2024:1‐14.
Tijms BM, Vromen EM, Mjaavatten O, et al. Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024:1‐15.